⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ATOS News
Atossa Therapeutics, Inc. Common Stock
Atos Strengthens Leadership in Data & AI in Spain as the Country Moves Towards AI at Scale
globenewswire.com
ATOS
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category
prnewswire.com
ATOS
Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium
prnewswire.com
ATOS
Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen
prnewswire.com
ATOS
Life Sciences BPO Market is expected to generate a revenue of USD 481.8 Billion by 2032, Globally, at 7.50% CAGR: Verified Market Research®
prnewswire.com
CTSH
ACN
IQV
INFY
RIVN
ATOS
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
prnewswire.com
ATOS
Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma
prnewswire.com
ATOS
CONMEBOL Welcomes Atos as Its New Official Innovation Partner for Club Competitions
globenewswire.com
ATOS
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
prnewswire.com
ATOS
Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
prnewswire.com
ATOS